Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. regarding potential securities fraud and other unlawful business practices by the company and certain officers and/or directors. The investigation centers on events surrounding the company's disclosure of clinical trial results on June 15, 2026, which triggered a significant decline in Elicio's stock price.

On June 15, 2026, Elicio issued a press release detailing results from its Phase 2 AMPLIFY-7P Study and outlining a refined Phase 3 development strategy for ELI-002 7P in adjuvant pancreatic cancer. The company stated that the AMPLIFY-7P study did not meet the pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat population.

Following this announcement, Elicio's stock price fell $9.97 per share, or 70.96%, to close at $4.08 per share on June 15, 2026. Investors who purchased securities of Elicio Therapeutics are advised to contact Danielle Peyton at Pomerantz LLP to discuss their rights.

Key Event Details

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is recognized as a premier firm in corporate, securities, and antitrust class litigation. The firm has recovered numerous multimillion-dollar damages awards on behalf of class members.

Elicio Therapeutics, Inc. has closed its previously announced registered direct offering, raising approximately $15 million in gross proceeds through the sale of 4,380,313 shares of its common stock. The clinical-stage biotechnology company is developing next-generation immunotherapies for KRAS-driven cancers. The offering was led by two new fundamental institutional investors with participation from a large existing shareholder. Titan Partners, a division of American Capital Partners, acted as the lead placement agent, while B. Riley Securities, Inc. served as the co-placement agent.

Elicio intends to use the net proceeds from the offering, along with its existing cash, cash equivalents, and marketable securities, to primarily fund the planned Phase 1 clinical development of ELI-002 7P in metastatic pancreatic ductal adenocarcinoma (PDAC). The funds will also support the company’s pipeline and platform, as well as working capital and general corporate purposes. ELI-002 is a structurally novel investigational AMP cancer immunotherapy targeting cancers driven by mutations in the KRAS-gene.

The offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-293861), which was initially filed with the Securities and Exchange Commission (SEC) on February 27, 2026, amended on March 2, 2026 and March 12, 2026, and declared effective on March 16, 2026. The shares of common stock were offered only by means of a prospectus supplement and accompanying prospectus forming a part of the effective registration statement.

Offering Details

About ELI-002 7P

Elicio’s lead product candidate, ELI-002 7P, is a 7-peptide formulation designed to provide immune response coverage against seven of the most common KRAS mutations present in 25% of all solid tumors. The candidate utilizes Elicio’s proprietary AMP technology, consisting of AMP-modified mutant KRAS peptide antigens and ELI-004, an AMP-modified CpG oligodeoxynucleotide adjuvant. Based on topline results and post-hoc analyses from the randomized Phase 2 AMPLIFY-7P trial, Elicio has refined its Phase 3 development strategy to focus on patients with lower residual disease burden and extended treatment duration. The company plans to initiate a Phase 1 study in metastatic PDAC to provide a rapid assessment of clinical activity.